Back to search

Aristotle University Of Thessaloniki (AUTH)

Η φαρμακοκινητική της σιπροφλοξασίνης σε ασθενείς με παρόξυνση χρόνιας αποφρακτικής πνευμονοπάθειας στη μονάδα εντατικής θεραπείας

Abstract

dc:description

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death worldwide and a major cause of chronic morbidity. COPD patients experience frequent and debilitating exacerbations of their disease, mainly of infectious origin. In some patients, mostly those with severe airflow obstruction, respiratory failure may occur and mechanical ventilation is sometimes necessary. Gram-negative enteric bacilli and mainly Pseudomonas spp. seem to have a prominent role in these severe exacerbations. Ciprofloxacin is considered to be one of the antibiotics of choice for the treatment of the respiratory infections, which are the cause of these severe exacerbations of COPD. Optimizing antimicrobial therapy in patients hospitalized in an Intensive Care Unit (ICU) can be difficult due to various pathophysiological changes that lead to altered and highly variable drug pharmacokinetics. In these critically ill patients and in the era of increasing antibiotic resistance, antibiotic therapy based on pharmacokinetics - pharmacodynamics becomes crucial. Regarding ciprofloxacin, the previously recommended dose of 800 mg per day has been increased to 1200 mg per day in critically ill patients because of inadequate serum levels and suboptimal pharmacodynamic exposure. Furthermore, antibiotic penetration into the site of infection is critical in order to achieve a favorable clinical outcome. Since in COPD patients the infection develops within the airway lumen, it is important to know the drug concentrations that are achieved in bronchial secretions. The purpose of this study is to investigate the pharmacokinetic profile of ciprofloxacin in critically ill patients with COPD exacerbation, to evaluate its penetration into their bronchial secretions and to calculate the pharmacodynamic parameters at various MIC of Gram-negative pathogens. Twenty-five mechanically ventilated patients were included in this prospective, open-label study. They were all suffering from an acute, infectious exacerbation of COPD and had risk factors for P. aeruginosa. All subjects received a 1-hour intravenous infusion of 400 mg ciprofloxacin q8h. Serial blood and bronchial secretions samples were obtained at steady state and concentrations were determined using high-performance liquid chromatography (HPLC). Plasma ciprofloxacin concentrations were plotted against time and the pharmacokinetic parameters were estimated by compartmental analysis using the WinNonlin software program. The penetration ratio for each patient was obtained by dividing the area under the curve from 0 to 24 h (AUC0→24) for bronchial secretions by the AUC0→24 for plasma. There was a large variability in the pharmacokinetic data. The mean peak and trough levels in plasma were 5.37 ± 1.57 and 1 ± 0.53 mg/L respectively. Mean values for volume of distribution, clearance, half-life and AUC0→24 were 169.9 ± 84.1 L, 27 ± 8.9 L/h, 5.35 ± 2.21 h and 47.41 ± 17.02 hrmg/L, respectively. In bronchial secretions, a mean Cmax of 3.08 ± 1.21 mg/L was observed in 3.12 ± 1.01 hours, while mean Cmin was found to be 0.88 ± 0.43 mg/L. The antibiotic penetrated well into bronchial secretions, achieving maximum concentrations that were 60 ± 25% of those in plasma and a penetration ratio of 1.16 ± 0.59. Moreover, in almost all patients the concentrations in bronchial secretions remained above 0.25 mg/L for the whole dosing interval, while in twenty or them they were ≥ 0.5 mg/L. As far as the pharmacodynamic parameters are concerned, the target of AUC0→24/MIC ≥ 125 was attained in all patients, in the majority of them (76%) and in none at MIC of 0.125, 0.25 and 1 μg/ml, respectively. Slightly better results were obtained for the target Cmax /MIC ≥ 10. Based on the microbiological data of our hospital, only 42% of P. aeruginosa strains had MIC ≤ 0.25 μg/ml, so the pharmacodynamics target of AUC0→24/MIC that is more frequently used, would be attained in less than half of the strains. In conclusion, ciprofloxacin demonstrates excellent penetration into bronchial secretions of critically ill COPD patients. There is wide interindividual variability in its pharmacokinetic parameters in this population and inadequate pharmacodynamic exposure against bacteria with MIC ≥ 0.5 μg/ml. Therefore, combination therapy is probably the best choice for the treatment of resistant pathogens, such as P. aeruginosa. The institution of therapeutic drug monitoring and the evaluation of the pharmacokinetics – pharmacodynamics of antibiotics, appear to be necessary for individualizing antimicrobial dosing in the ICU, in order to optimize efficacy and to prevent the development of resistance.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kontou, Paschalina
  • Κοντού, Πασχαλίνα

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/25716

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kontou, Paschalina; Κοντού, Πασχαλίνα. Η φαρμακοκινητική της σιπροφλοξασίνης σε ασθενείς με παρόξυνση χρόνιας αποφρακτικής πνευμονοπάθειας στη μονάδα εντατικής θεραπείας. Aristotle University Of Thessaloniki (AUTH), 2011. http://hdl.handle.net/10442/hedi/25716